AER 1601082 is a spontaneous case, received on 29/Jun/2015 from a physician via a company representative 
(source identification number: 415098) and concerns a male patient of an unspecified age who developed bilateral 
arm paresis and suspected progressive multifocal leukoencephalopathy whilst being treated with rituximab 
(Mabthera) and bendamustine (Bendamustine).
The patient's medical history, past drugs, concurrent conditions and concomitant medications were not reported.
On an unspecified date, the patient started therapy with rituximab and bendamustine (route, form, dose and 
frequency not reported for both) for marginal zone lymphoma. It was reported that, he received an induction 
treatment with rituximab and bendamustine followed by 2 years of maintenance therapy with rituximab. Later, he 
suffered from pronounced bilateral arm paresis and progressive multifocal leukoencephalopathy was suspected 
(reported as suspected progressive multifocal leukoencephalopathy). It was reported that, liquor puncture was 
planned.
At the time of this report, bilateral arm paresis was persisting and the outcome of suspected progressive multifocal 
leukoencephalopathy was not reported. The therapy status of rituximab and bendamustine was unknown.
The physician did not assessed the causal relationship of the events bilateral arm paresis and suspected 
progressive multifocal leukoencephalopathy with rituximab and bendamustine.
The company assessed the events bilateral arm paresis and suspected progressive multifocal 
leukoencephalopathy as medically significant.
No further information was provided.